SIMpill Medication Dispensing Device in the Treatment of HCV (SIMpill HCV)

This study has been withdrawn prior to enrollment.
(No subjects enrolled due to delay in device production)
Sponsor:
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT01691235
First received: September 17, 2012
Last updated: October 6, 2014
Last verified: October 2014

September 17, 2012
October 6, 2014
September 2012
January 2013   (final data collection date for primary outcome measure)
Improved SVR Rates [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To determine if the Simpill devise will improve viral kinetics from week 0 to week 4, leading to improved SVR rates.
Same as current
Complete list of historical versions of study NCT01691235 on ClinicalTrials.gov Archive Site
Improved Patient Adherence Rates [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To determine overall adherence rates among patients taking telaprevir
Same as current
Not Provided
Not Provided
 
SIMpill Medication Dispensing Device in the Treatment of HCV
Evaluation of the SIMpill Medication Dispensing Device in the Treatment of Chronic Hepatitis C

Subjects are being asked to participate in this study because they have genotype 1 Hepatitis C Virus (HCV) and will be taking the standard of care drugs pegylated interferon, ribavirin, and telaprevir as part of their routine care. The purpose of this study is to see if the SIMpill automated pill dispensing device can help subjects take their medications at the times the doctor has instructed them to take it.

The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. Physicians can download this data and generate a precise account of when you have taken your medication. In addition, if a dose is missed, the SIMpill device can be set to automatically notify you by text message if a dose is overdue. The Simpill device is a new way to keep track of when you take your HCV medications and will also help remind you when you forget to take a dose. In addition, this information will help your doctors understand how taking medication on time effects the success of the therapy.

  • Patients with genotype 1 HCV who are candidates for therapy with telaprevir, pegylated interferon and ribavirin will be eligible for the study.
  • All patients enrolled in this study will receive a standard of care regimen of telaprevir /pegylated interferon and ribavirin. This includes medication dosages, follow-up, and monitoring. The only exception will be the mode of medication dispensing.
  • Patients will be asked to bring their Simpill devices to their regularly scheduled clinic visits at which time medication adherence information will be downloaded by study personnel. Each visit will be a regularly scheduled standard of care visit and no additional clinic visits will be needed for the patient in the Simpill study arm.
  • In the event that any patient demonstrated viral breakthrough during therapy, those patients will be offered an additional blood draw to screen for viral resistance. This will be important to understand if patients using the Simpill device have better adherence to the medication regiment which results in lower incidence of viral resistance.
  • Patients in the study arm will receive a text messages each time a dose of medication is missed. This message will only go to the telephone number specified by the patient and will not go to members of the study team. Patients who do not have text messaging capability will not be eligible for this study.
  • The initial study will be a pilot study designed to obtain preliminary data regarding the feasibility of this device. This study is powered to detect differences in viral kinetics over the first 4 weeks.
  • In the event that Vertex receives FDA approval for BID dosage of telaprevir prior to funding and initiation of the study, the most currently approved dosing (BID) will be used instead of q8 hours.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

A blood draw (about 1 tablespoon) if the medication is not working for a subject. This blood draw is another way for the study team to measure adherence to the therapy. This blood draw will be taken only once at the time HCV in the blood return to high levels. This blood draw will measure HCV resistance.

Probability Sample

Subjects will be recruited from the outpatient/inpatient Liver GI clinic at the University of Chicago Medical Center

Chronic Hepatitis C Virus
Device: SIMpill device
The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
  • Arm 1
    Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
    Intervention: Device: SIMpill device
  • Arm 2
    Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients age 18 - 70 with genotype 1 HCV
  • Compensated liver disease who are independently deemed an appropriate candidate for telaprevir containing HCV treatment regimen

Exclusion Criteria:

  • Prior liver transplantation
  • Co-infection with other types of viral hepatitis and HIV
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01691235
12-1293
No
University of Chicago
University of Chicago
Not Provided
Principal Investigator: Andrew Aronsohn, MD University of Chicago
University of Chicago
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP